Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cladribine
Drug ID BADD_D00479
Description An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
Indications and Usage For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
Marketing Status Prescription; Discontinued
ATC Code L01BB04; L04AA40
DrugBank ID DB00242
KEGG ID D01370
MeSH ID D017338
PubChem ID 20279
TTD Drug ID D05GJW
NDC Product Code 65129-1260; 67457-450; 63323-140; 42658-010; 54893-0115; 59605-3006; 58623-0037; 12502-4912; 0143-9871; 12502-5406; 44087-4000
Synonyms Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin
Chemical Information
Molecular Formula C10H12ClN5O3
CAS Registry Number 4291-63-8
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypertension24.08.02.0010.001095%
Hyperthyroidism14.11.01.011; 05.02.02.0010.000730%
Hyperuricaemia14.09.01.003--
Hypoaesthesia17.02.06.0230.001825%Not Available
Hypotension24.06.03.002--
Hypothyroidism14.11.01.012; 05.02.03.0010.000730%
Ileus07.13.01.001--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.000762%Not Available
Infection masked11.01.08.047; 10.02.01.045--Not Available
Influenza22.07.02.001; 11.05.03.0010.000730%Not Available
Influenza like illness08.01.03.0100.000730%
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia17.15.03.002; 19.02.01.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.0010.003284%Not Available
Leukoplakia oral07.05.01.0090.000730%Not Available
Localised infection11.01.08.006--Not Available
Lower respiratory tract infection22.07.01.002; 11.01.09.0020.001095%Not Available
Lung infiltration22.01.02.004--Not Available
Lymphocyte count decreased13.01.06.0060.009488%
Lymphopenia01.02.02.0020.008393%Not Available
Malaise08.01.01.0030.001825%
Malignant melanoma23.08.01.001; 16.03.01.0010.000730%Not Available
Metabolic acidosis14.01.01.003--Not Available
Migraine17.14.02.001; 24.03.05.0030.001460%Not Available
Mucosal inflammation08.01.06.002--Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.002189%Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 9 Pages